Regulation 30 & 34 (1) of SEBI (LODR) Regulations ,2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts less than Nifty Microcap 250 and 7.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unjha Formulations has filed its 31st Annual Report for FY2024-25 along with the notice of the 31st Annual General Meeting scheduled for August 13, 2025. Total income declined to Rs. 13.98 Cr from Rs. 18.51 Cr in the previous year, roughly a 24% drop in turnover. Despite the revenue fall, profit after tax rose 46% to Rs. 40.75 Lacs from Rs. 27.79 Lacs, aided by lower depreciation and tax outgo. The company continues to carry accumulated losses of Rs. 134.18 Lacs and has skipped dividend to conserve resources. A related party contract with Urvesh & Company for sale/purchase of Psyllium Husk worth Rs. 1 Cr is being placed before shareholders for approval, and M/s. Ajay Parikh & Associates is proposed as the new secretarial auditor for a five-year term.
Sharp revenue contraction despite higher profits is a mixed signal for shareholders and may weigh on the stock. The decision to skip dividend and seek shareholder approval for related party transactions warrants attention at the upcoming AGM.